# A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

> **NCT01671488** · PHASE1,PHASE2 · TERMINATED · sponsor: **Brown University** · enrollment: 11 (actual)

## Conditions studied

- Anal Cancer

## Interventions

- **BIOLOGICAL:** Treatment
- **DRUG:** 5FU
- **DRUG:** Mitomycin
- **RADIATION:** IMRT

## Key facts

- **NCT ID:** NCT01671488
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** pilot data to be used for upcoming larger trial.
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01671488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01671488, "A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01671488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*